Whitehawk Therapeutics, Inc. (WHWK)
NASDAQ: WHWK · Real-Time Price · USD
3.030
-0.050 (-1.62%)
Nov 11, 2026, 10:14 AM EST - Market open
Whitehawk Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 7.15 | 25.98 | 24.35 | 15.22 | 1.12 | |
Revenue Growth | - | -72.50% | 6.69% | 60.05% | 1258.57% | -92.32% |
Cost of Revenue | - | 0.76 | 3.02 | 51.74 | 34 | 19.67 |
Gross Profit | - | 6.39 | 22.96 | -27.38 | -18.78 | -18.55 |
Selling, General & Admin | 22.18 | 29.82 | 36.75 | 44.55 | 40.18 | 18.51 |
Research & Development | 67.28 | 90.96 | 51.03 | - | - | - |
Operating Expenses | 89.46 | 120.79 | 87.78 | 44.55 | 40.18 | 18.51 |
Operating Income | -89.46 | -114.4 | -64.82 | -71.93 | -58.96 | -37.06 |
Interest Expense | - | - | -0.15 | -0.23 | -0.23 | -0.67 |
Interest & Investment Income | 6.15 | 6.23 | 3.93 | 6.4 | 2.4 | 0.01 |
Currency Exchange Gain (Loss) | -0 | 0.01 | -0 | -0 | - | - |
Other Non Operating Income (Expenses) | 0.02 | 0.3 | - | - | - | - |
EBT Excluding Unusual Items | -83.29 | -107.86 | -61.05 | -65.77 | -56.79 | -37.71 |
Merger & Restructuring Charges | - | - | -2.64 | - | - | - |
Gain (Loss) on Sale of Assets | - | 87.27 | - | - | - | - |
Asset Writedown | - | - | - | - | -3.72 | -74.16 |
Other Unusual Items | - | - | - | - | - | 1.78 |
Pretax Income | -83.29 | -20.6 | -63.69 | -65.77 | -60.51 | -110.09 |
Income Tax Expense | - | - | - | - | - | 0 |
Net Income | -83.29 | -20.6 | -63.69 | -65.77 | -60.51 | -110.09 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.65 |
Net Income to Common | -83.29 | -20.6 | -63.69 | -65.77 | -60.51 | -110.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 79 | 62 | 27 | 27 | 23 | 9 |
Shares Outstanding (Diluted) | 79 | 62 | 27 | 27 | 23 | 9 |
Shares Change | 53.67% | 128.96% | 0.42% | 19.58% | 152.27% | 250.99% |
EPS (Basic) | -1.06 | -0.33 | -2.36 | -2.44 | -2.69 | -12.41 |
EPS (Diluted) | -1.06 | -0.33 | -2.36 | -2.44 | -2.69 | -12.41 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -73.65 | -97.99 | -61.2 | -63.64 | -50.08 | -22.47 |
Free Cash Flow Per Share | -0.93 | -1.58 | -2.26 | -2.36 | -2.23 | -2.52 |
Gross Margin | - | 89.36% | 88.36% | -112.44% | -123.43% | - |
Operating Margin | - | -1601.12% | -249.47% | -295.36% | -387.47% | -3309.02% |
Profit Margin | - | -288.26% | -245.13% | -270.04% | -397.69% | -9887.23% |
Free Cash Flow Margin | - | -1371.38% | -235.55% | -261.29% | -329.15% | -2006.16% |
EBITDA | -89.46 | -114.32 | -64.63 | -71.76 | -58.8 | -36.96 |
EBITDA Margin | - | - | -248.73% | -294.67% | - | - |
D&A For EBITDA | 0 | 0.08 | 0.19 | 0.17 | 0.16 | 0.11 |
EBIT | -89.46 | -114.4 | -64.82 | -71.93 | -58.96 | -37.06 |
EBIT Margin | - | - | -249.47% | -295.36% | - | - |
Revenue as Reported | - | 7.15 | 25.98 | 24.35 | 15.22 | 1.12 |